[HTML][HTML] Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 …
VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn… - Annals of …, 2020 - Elsevier
Background In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …
[HTML][HTML] Real-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients …
K Cuppens, L Lodewyckx, I Demedts… - Drugs-real world …, 2021 - Springer
Background Treatment of patients with epidermal growth factor receptor-mutated (EGFRm)
non-small cell lung cancer (NSCLC) continues to evolve expeditiously. Objectives This …
non-small cell lung cancer (NSCLC) continues to evolve expeditiously. Objectives This …
Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
SH How, CK Liam, MA Zainal Abidin… - Cancer management …, 2022 - Taylor & Francis
Background Although first-and second-generation EGFR TKIs are considered first-line
treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly …
treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly …
[HTML][HTML] Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients
K Khiewngam, S Oranratnachai, K Kamprerasart… - Frontiers in …, 2023 - frontiersin.org
Background Despite significant benefits of epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) treatment in patients with EGFR-mutated NSCLC, access remains …
inhibitor (EGFR-TKI) treatment in patients with EGFR-mutated NSCLC, access remains …
[HTML][HTML] A comprehensive next generation sequencing tissue assay for Asian-prevalent cancers—Analytical validation and performance evaluation with clinical …
CCY Ng, S Lim, AH Lim, ND Md Nasir… - Frontiers in Molecular …, 2022 - frontiersin.org
A well-validated diagnostic assay with curated biomarkers complements clinicopathological
factors to facilitate early diagnosis and ensure timely treatment delivery. This study focuses …
factors to facilitate early diagnosis and ensure timely treatment delivery. This study focuses …
[HTML][HTML] Клинический случай длительного применения осимертиниба при лечении EGFR-положительной аденокарциномы легкого
СВ Одинцова, МА Свириденко… - Современная …, 2020 - cyberleninka.ru
В данной статье рассмотрены клинический случай EGFR-положительного
немелкоклеточного рака легкого и его лечение препаратом осимертиниб. Таргетные …
немелкоклеточного рака легкого и его лечение препаратом осимертиниб. Таргетные …
Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
SV Odintsova, MA Sviridenko… - Journal of Modern …, 2020 - modernonco.orscience.ru
This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-
positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted …
positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted …